genes may predict trastuzumab outcomes in breast cancer
Published 11 years ago • 208 plays • Length 3:00Download video MP4
Download video MP3
Similar videos
-
6:13
cleopatra: success with dual her2 blockade in breast cancer
-
1:21
katherine trial tests trastuzumab emtansine in breast cancer recurrence
-
3:04
biomarkers in breast cancer
-
9:17
san antonio roundtable, part 3: trastuzumab, bevacizumab, and angiogenesis inhibitors
-
4:15
identifying genes that can predict if breast cancer drug is working - mayo clinic
-
4:20
immune function marker does not predict benefit of trastuzumab in her breast cancer patients
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
0:59
sequencing her2-targeted therapies in breast cancer
-
5:05
anti-her2 mechanisms of approved her2 inhibitors
-
3:54
unmet treatment needs in subgroups of patients with multiple myeloma
-
6:47
how to select treatment for her2 breast cancer patients with brain metastasis?
-
5:29
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
2:06
mimosa: monalizumab and trastuzumab in her2 breast cancer
-
19:09
breast cancer predisposition genes and beyond: role in prevention and treatment
-
8:31
#esmo21 expert video report on her2-positive early breast cancer
-
32:09
grands rounds in the age of covid-19; cardiotoxicity in breast cancer
-
5:03
transplant patient selection & mds 2020 higlights
-
2:14
dr. pegram on sequencing therapies in her2-positive breast cancer
-
1:07:43
new & supporting data for optimizing therapy in her2 breast cancer | dr. mahtani & dr. schwartzberg
-
6:46
a presurgery combination therapy may improve outcomes for women with her2 positive breast cancer
-
1:56
promising approaches and clinical trials in mds